REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

C. Lepage; L. Dahan; J.-L. Legoux; K. Le Malicot; R. Guimbaud; D. Tougeron; A. Lievre; N. Bouarioua; C. Petorin; M. Pavel; I. Borbath; C. Toumpanakis; D. Smith; M. Ducreux; T. Walter

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

C. Lepage ¹ L. Dahan ² J.-L. Legoux ³ K. Le Malicot ⁴ R. Guimbaud ⁵ D. Tougeron ⁶ A. Lievre ⁷ N. Bouarioua ⁸ C. Petorin ⁹ M. Pavel ¹⁰ I. Borbath ¹¹ C. Toumpanakis ¹² D. Smith ¹³ M. Ducreux ¹⁴ T. Walter ¹⁵

1 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand

2 TIMONE - Hôpital de la Timone [CHU - APHM]

3 CHR - Centre Hospitalier Régional d'Orléans

4 Fédération Francophone de la Cancérologie Digestive, FFCD

5 CHU Toulouse [Toulouse]

6 CHU Poitiers - Centre hospitalier universitaire de Poitiers

7 CHU Pontchaillou [Rennes]

8 CHU de Saint-Etienne - Centre Hospitalier Universitaire de Saint-Etienne

9 CHU Clermont-Ferrand

10 Charite-Universitatsmedizin Berlin [Berlin]

11 Cliniques universitaires St Luc [Bruxelles]

12 The Royal Free Hospital

13 CHU Bordeaux [Bordeaux]

14 Oncologie digestive

Département de médecine oncologique [Gustave Roussy]

15 HCL - Hospices Civils de Lyon

Keywords : Maintenance Clinical trial Duodeno-pancreatic neuroendocrine tumours

Type de document :

Communication dans un congrès

The 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2017, Barcelone, Spain. Neuroendocrinology, 105 (Suppl. 1), pp.187 (J8), 2017, 〈https://www.karger.com/Article/Pdf/484263〉

Domaine :

Sciences du Vivant [q-bio] / Médecine humaine et pathologie / Endocrinologie et métabolisme

Liste complète des métadonnées

https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01664217
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 14 décembre 2017 - 15:52:55
Dernière modification le : vendredi 27 juillet 2018 - 15:04:02

C. Lepage, L. Dahan, J.-L. Legoux, K. Le Malicot, R. Guimbaud, et al.. REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors . The 14th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Mar 2017, Barcelone, Spain. Neuroendocrinology, 105 (Suppl. 1), pp.187 (J8), 2017, 〈https://www.karger.com/Article/Pdf/484263〉. 〈hal-01664217〉

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Identifiants

Collections

Citation

Exporter

Métriques

64

Contact

REMINET : A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Identifiants

Collections

Citation

Exporter

Partager

Métriques

64

Contact